Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:LXRXNASDAQ:VNDANASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.06-1.1%$2.10$1.38▼$19.69$76.81M1.58576,167 shs42,201 shsLXRXLexicon Pharmaceuticals$0.68-5.3%$0.49$0.28▼$2.45$247.62M1.076.46 million shs739,566 shsVNDAVanda Pharmaceuticals$4.48-2.4%$4.56$3.85▼$6.75$263.44M0.69755,876 shs56,354 shsVSTMVerastem$6.91-1.4%$6.26$2.10▼$13.52$355.02M0.571.03 million shs210,743 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-0.64%-1.59%+98.08%-11.71%-76.36%LXRXLexicon Pharmaceuticals+5.79%+4.65%+71.88%-5.28%-58.62%VNDAVanda Pharmaceuticals+0.44%+6.74%+10.87%+2.46%-5.94%VSTMVerastem-5.65%+0.29%+35.85%+19.42%-35.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.376 of 5 stars3.11.00.04.61.71.70.6LXRXLexicon Pharmaceuticals3.2762 of 5 stars4.24.00.00.02.41.70.6VNDAVanda Pharmaceuticals4.1563 of 5 stars3.51.00.04.22.03.31.3VSTMVerastem3.143 of 5 stars4.51.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$8.75186.42% UpsideLXRXLexicon Pharmaceuticals 2.40Hold$3.67437.63% UpsideVNDAVanda Pharmaceuticals 3.00Buy$16.50268.39% UpsideVSTMVerastem 3.00Buy$13.89100.97% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, VNDA, LXRX, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.004/1/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025VSTMVerastemRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.003/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $3.00(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M0.75N/AN/A($7.78) per share-0.39LXRXLexicon Pharmaceuticals$31.08M7.93N/AN/A$0.38 per share1.79VNDAVanda Pharmaceuticals$198.77M1.33N/AN/A$9.23 per share0.49VSTMVerastem$10M35.58N/AN/A$2.27 per share3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$10.68N/AN/AN/A-145.89%N/A-85.68%5/12/2025 (Estimated)LXRXLexicon Pharmaceuticals-$177.12M-$0.64N/AN/AN/A-4,109.41%-107.38%-64.09%N/AVNDAVanda Pharmaceuticals-$18.90M-$0.32N/AN/AN/A-9.51%-3.49%-2.90%5/7/2025 (Estimated)VSTMVerastem-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%5/8/2025 (Estimated)Latest AGEN, VNDA, LXRX, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AGENAgenus-$1.72N/AN/AN/A$26.38 millionN/A5/8/2025Q1 2025VSTMVerastem-$0.65N/AN/AN/A$0.10 millionN/A5/7/2025Q1 2025VNDAVanda Pharmaceuticals$0.05N/AN/AN/A$45.13 millionN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 million3/6/2025Q4 2024LXRXLexicon Pharmaceuticals-$0.11-$0.09+$0.02-$0.09$6.48 million$26.55 million2/13/2025Q4 2024VNDAVanda Pharmaceuticals-$0.14-$0.08+$0.06-$0.08$51.00 million$53.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19LXRXLexicon Pharmaceuticals0.567.457.43VNDAVanda PharmaceuticalsN/A4.394.37VSTMVerastem2.773.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%LXRXLexicon Pharmaceuticals74.70%VNDAVanda Pharmaceuticals88.14%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipAGENAgenus4.60%LXRXLexicon Pharmaceuticals6.80%VNDAVanda Pharmaceuticals8.90%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44025.31 million22.38 millionOptionableLXRXLexicon Pharmaceuticals140361.49 million229.49 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.13 millionOptionableVSTMVerastem5051.49 million43.53 millionOptionableAGEN, VNDA, LXRX, and VSTM HeadlinesRecent News About These CompaniesVerastem, Inc. (NASDAQ:VSTM) Holdings Boosted by BVF Inc. ILMay 6 at 7:31 AM | marketbeat.comB. Riley Has Pessimistic Outlook of Verastem Q2 EarningsMay 3 at 7:12 AM | marketbeat.comVerastem (VSTM) to Release Earnings on ThursdayMay 3 at 3:24 AM | marketbeat.comB. Riley Has Optimistic Outlook of Verastem FY2029 EarningsMay 2, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesMay 2, 2025 | finance.yahoo.comB. Riley Issues Negative Forecast for Verastem EarningsMay 2, 2025 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLCApril 28, 2025 | marketbeat.comMarshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)April 27, 2025 | marketbeat.comVerastem Oncology Announces $75 million Private Placement | VSTM Stock NewsApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | finance.yahoo.comVerastem Oncology rises on $75M private placementApril 25, 2025 | seekingalpha.comVerastem announces U.S. IND clearance of VS-7375April 25, 2025 | markets.businessinsider.comVerastem, Inc. (NASDAQ:VSTM) Shares Sold by Walleye Capital LLCApril 24, 2025 | marketbeat.comVerastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer TreatmentApril 23, 2025 | marketwatch.comVerastem Oncology to initiate trial for its targeted cancer therapyApril 23, 2025 | msn.comVerastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375April 23, 2025 | gurufocus.comVerastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA Approval | VSTM Stock NewsApril 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, ...April 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid TumorsApril 23, 2025 | businesswire.comVerastem Oncology to Report Q1 Earnings: What's in the Cards?April 22, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumIONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadBy Leo Miller | April 12, 2025View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadAGEN, VNDA, LXRX, and VSTM Company DescriptionsAgenus NASDAQ:AGEN$3.06 -0.04 (-1.13%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$0.68 -0.04 (-5.28%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Vanda Pharmaceuticals NASDAQ:VNDA$4.48 -0.11 (-2.42%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Verastem NASDAQ:VSTM$6.91 -0.10 (-1.41%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Chevron’s Fundamentals Shine Through Market Turmoil Monster Beverage Stock: Short Report Risks vs Upside Potential Onsemi Stock Confirms Bottom, But What’s the Upside? 3 Reasons Tesla Should Be a $300 Stock by June Qualcomm: Analyst Opinions Split, But Upside Potential Remains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
